Altre lingue Affimed N.V.

Azioni

AFMD

NL0015001ZQ0

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
5,33 ^USD	-0,37%		+9,22%	-14,72%

01/04	AFFIMED N.V. : Wells Fargo Securities ottimista sul caso	ZM
01/04	AFFIMED N.V. : HC Wainwright è per il Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	24/04
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed Reports 2023 Financial Results and Operational Progress	28/03
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	21/03
Affimed N : Form 6-K	11/03
Affimed Announces 1-for-10 Reverse Stock Split	06/03
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	09/01
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	08/01
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	08/01
Affimed Announces Leadership Change and Organizational Restructuring	08/01
Affimed N.V. Announces CEO Changes	08/01
Affimed N.V. Announces Management Changes	08/01
Sector Update: Health Care Stocks Mixed Late Afternoon	03/01
Sector Update: Health Care Stocks Gain in Afternoon Trading	03/01
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	03/01
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	03/01
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	03/01
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index	15/12
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS	12/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Affimed N.V.

Azioni

AFMD

NL0015001ZQ0

Altre lingue

Filtri